A review of parenteral sustained-release naltrexone systems.
A review of parenteral sustained-release naltrexone systems.
复制标题
肠外缓释纳曲酮系统的综述。
DOI：
--
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
F. Kincl
中科院分区：
文献类型：
--
作者：
J. L. Olsen;F. Kincl
理想的纳曲酮缓释递送系统应易于注射或植入，不引起组织不良反应，至少30天内以相对恒定的速率释放药物，并在随后的短时间内生物降解。可用于维持药物释放的机制包括降低溶解度和表面积、包衣、包囊和微囊化、络合、结合和亲水凝胶化。药物从此类系统的释放是通过穿过屏障/薄膜的扩散、从整体装置的扩散、表面侵蚀、水解、离子交换、生物降解或这些的组合来控制的。由于易于管理和操作，注射系统似乎最终会受到青睐，而植入式装置可能会首先在人体中使用，因为如果有必要的话，它们很容易移除。保持产品无颗粒和灭菌方法是所有肠胃外剂型的两个问题。生产必须得到特别良好的控制和验证。
The ideal naltrexone sustained-release delivery system should be easy to inject or implant, not cause adverse tissue reaction, release the drug at a relatively constant rate for at least 30 days, and biodegrade within a short time afterwards. Mechanisms which can be used for sustaining drug release include reducing solubility and surface area, coating, encapsulation and microencapsulation, complexation, binding and hydrophilic gelation. Drug release from such systems is controlled by diffusion through a barrier/film, diffusion from a monolithic device, erosion of the surface, hydrolysis, ion exchange, biodegradation, or a combination of these. Injectable systems would seem to be ultimately preferred because of the ease of administration and handling, while the implantable devices may find first use in man since they are easily removable, should that be necessary. Maintaining particulate-free products and sterilization methods are two problems with all parenteral dosage forms. Production must be particularly well controlled and validated.